ARQT | Ticker Profile - Titan Protect

ARQT

Arcutis Biotherapeutics, Inc.

Healthcare · Biotechnology · NMS

$21.23

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

18.30

Based on estimated future earnings — lower means cheaper

Rev Growth

+60.1%

Year-over-year revenue change

Profit Margin

-0.6%

How much profit the company keeps from each dollar of revenue

ROE

-1.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.00

+65% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 8 analysts covering this stock

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

https://www.arcutis.com

Country: United States Employees: 354 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.026

Excellent risk-adjusted returns

Kelly Fraction

0.0711

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.558

Returns exceed worst-case losses — strong risk profile

Annual Return

58.4%

Historical annualised return based on price data

Max Drawdown

-37.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.59

Significantly more volatile than the market

52W High

$31.77

33% below the year high

52W Low

$12.72

67% above the year low

Avg Volume

1,552,383

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.02

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

60.47

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.68

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.26

Like current ratio but excludes inventory — stricter test

Gross Margin

90.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-8.6%

Profit from core operations before interest and tax

Free Cash Flow

$4M

Positive — the business generates more cash than it spends

Revenue (TTM)

$416M

Total revenue over the last 12 months

Net Income

$-2,376,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$36.00

Target Median

$35.00

Target Low

$33.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go